ClinicalTrials.gg
CompletedNCT02951429Updated Nov 12, 2020Results posted

Efficacy, Safety, and Tolerability Study of Pirfenidone in Combination With Sildenafil in Participants With Advanced Idiopathic Pulmonary Fibrosis (IPF) and Intermediate or High Probability of Group 3 Pulmonary Hypertension

A Phase 2 interventional study of Pirfenidone and Placebo in Idiopathic Pulmonary Fibrosis, sponsored by Hoffmann-La Roche. Completed at 56 sites in 13 countries. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2020-11-12.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
177
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies in Idiopathic Pulmonary Fibrosis by Hoffmann-La Roche — none open to participants now, none under way, none of them phase 3. Idiopathic Pulmonary Fibrosis · Hoffmann-La Roche.

Enrollment
12th of 24
177 · median 150
Started
2016
with 2 others
Phase 2
9 of 29
none open now
Registered
23rd of 29
by date

Among the 29 studies in Idiopathic Pulmonary Fibrosis by Hoffmann-La Roche, this one is the 12th largest by enrollment of the 24 interventional ones that give a count, is one of 3 that started in 2016, is one of 9 in phase 2, and was the 23rd registered.

Idiopathic Pulmonary Fibrosis

577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 124 are open to participants now.

Browse Idiopathic Pulmonary Fibrosis studies →

Open to participants now

None of the 29 studies in Idiopathic Pulmonary Fibrosis by Hoffmann-La Roche is open now. The open studies under Idiopathic Pulmonary Fibrosis, anywhere →

Who these studies take

Of the 86 Idiopathic Pulmonary Fibrosis studies recruiting now, 56 (65%) set no upper age limit and 8 (9%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.

This study: 40 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 29 studies in Idiopathic Pulmonary Fibrosis by Hoffmann-La Roche as a file.
02

Study summary

This Phase IIb, randomized, placebo-controlled, multicenter, international study will evaluate the efficacy, safety, and tolerability of sildenafil or placebo added to pirfenidone (Esbriet) treatment in participants with advanced IPF and intermediate or high probability of Group 3 pulmonary hypertension (PH) who are on a stable dose of pirfenidone with demonstrated tolerability. Participants will be randomized to receive 1 year of treatment with either oral sildenafil or matching placebo while continuing to take pirfenidone.

03

Conditions studied

  • Idiopathic Pulmonary Fibrosis
04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of IPF for at least 3 months prior to Screening
  • Confirmation of IPF diagnosis by the investigator in accordance with the 2011 international consensus guidelines at screening
  • Advanced IPF (defined as a measurable carbon monoxide diffusing capacity [DLCO] less than or equal to (\<=)40% of predicted value at Screening) and intermediate or high probability of group 3 pulmonary hypertension (PH)
  • Participants receiving pirfenidone for at least 12 weeks, at a dose in the range of 1602 to 2403 mg/day for at least 4 weeks prior to Screening and must not have experienced either a new or ongoing adverse event of National Cancer Institute (NCI CTCAE) (version 4.03) Grade 2 or higher and considered by the investigator to be related to pirfenidone, or an interruption of pirfenidone treatment of greater than (>)7 days for any reason
  • WHO Functional Class II or III at Screening
  • 6MWD of 100 to 450 meters at screening
  • Women of and for men who are not surgically sterile agreement to remain abstinent or use of measures

Exclusion criteria

Exclusion Criteria:

  • History of any of the following types of PH: Group 1 (PAH); Group 1 (pulmonary veno-occlusive disease and/or pulmonary capillary hemangiomatosis); Group 2 (left-heart disease); Group 3 (due to conditions other than interstitial lung disease, including [COPD], sleep-disordered breathing, alveolar hypoventilation, high altitude, or developmental abnormalities); Group 4 (chronic thromboembolic pulmonary hypertension); Group 5 (other disorders)
  • History of cardiac disease
  • History of coexistent and clinically significant COPD, bronchiectasis, asthma, inadequately treated sleep-disordered breathing, or any clinically significant pulmonary diseases or disorders other than IPF or PH secondary to IPF
  • History of use of drugs and toxins known to cause PAH, including aminorex, fenfluramine, dexenfluramine, and amphetamines
  • /FVC ratio less than (\<) 0.70 post bronchodilator; SpO2 saturation at rest \<92% with >= 6 liters (L) of supplemental oxygen at Screening
  • Extent of emphysema greater than the extent of fibrotic changes (honeycombing and reticular changes) on any previous high-resolution computed tomography (HRCT) scan, in the opinion of the Investigator
  • Smoked tobacco within 3 months prior to screening or is unwilling to avoid tobacco products (cigarettes, pipe, cigars) throughout the study
  • Illicit drug or significant alcohol abuse
  • (ECG) with a heart-rate interval (corrected using Fridericia's formula [QTcF]) >=500 milliseconds (ms) at screening, or a family or personal history of long QT syndrome
  • Exclusion criteria based on pirfenidone reference safety information: 1. participants with a history of angioedema due to pirfenidone; 2. concomitant use of fluvoxamine
  • Exclusion criteria based on sildenafil reference safety information: 1. co-administration with nitric oxide donors or organic nitrates, phosphodiesterase-5 (PDE5) inhibitors, guanylate cyclase stimulators, and most potent of the Cytochrome P450 3A4 () inhibitors; 2. loss of vision in one eye because of non-arteritic anterior ischemic optic neuropathy (NAION); 3. use of an alpha-blocker; 4. participants with bleeding disorders or active peptic ulceration; 5. known hereditary degenerative retinal disorders such as retinitis pigmentosa; 6. galactose intolerance
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
177 participants (actual)

Study arms

  • Placebo comparator
    Pirfenidone + Placebo

    Participants will receive pirfenidone along with placebo matched to sildenafil, orally, three times a day (TID) for 52 weeks.

    Drug: Pirfenidone · Drug: Placebo

  • Experimental
    Pirfenidone + Sildenafil

    Participants will receive pirfenidone along with sildenafil, orally, TID for 52 weeks.

    Drug: Pirfenidone · Drug: Sildenafil

Interventions

  • Pirfenidone will be given in the range of 1602 to 2403 milligram per day (mg/day), as 3 divided doses.

    Also known as: Esbriet, RO0220912

  • DrugPlacebo

    Placebo matched with sildenafil.

  • Sildenafil will be given as 20 mg, TID.

    Also known as: RO0280296

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Disease Progression, as Determined by Relevant Decline in 6 Minute Walk Distance (6MWD) of At Least (>=) 15 Percent (%) From Baseline, Respiratory-Related Non-Elective Hospitalization, or Death From Any Cause

    Disease Progression defined as relative decline in 6-minute walking distance (6MWD) from baseline (defined as \>25% from baseline or 15-25% from baseline associated with worsening oxygen saturation, worsening Borg score, or increased oxygen requirements), respiratory-related non-elective hospitalizations, or all-cause mortality.

    Time frame: Baseline up to Week 52

Secondary outcomes

  1. Time to First Occurrence of Disease Progression

    Disease Progression defined as relative decline in 6MWD from baseline (defined as \>25% from baseline or 15-25% from baseline associated with worsening oxygen saturation, worsening Borg score, or increased oxygen requirements), respiratory-related non-elective hospitalizations, or all-cause mortality.

    Time frame: Baseline up to Week 52

  2. Time to Multiple Occurrence of Disease Progression Events

    Disease Progression defined as relative decline in 6MWD from baseline (defined as \>25% from baseline or 15-25% from baseline associated with worsening oxygen saturation, worsening Borg score, or increased oxygen requirements), respiratory-related non-elective hospitalizations, or all-cause mortality. In case participant had more than one event as described in the endpoint definition the second, third etc event was counted as well for the calculation of the endpoint.

    Time frame: Baseline up to Week 52

  3. Percentage of Participants With Decline From Baseline in 6-minute Walking Distance (6MWD) of >= 15%

    Time frame: Baseline up to Week 52

  4. Time to First Occurrence of Relevant ≥15% Decline From Baseline in 6-minute Walking Distance (6MWD)

    Time frame: Baseline up to Week 52

  5. Time to Respiratory-Related Non-Elective Hospitalization From Baseline to Week 52

    N.A. = non-calculable

    Time frame: Baseline up to Week 52

  6. Time to All-Cause Non-Elective Hospitalization

    N.A. = non-calculable

    Time frame: Baseline up to Week 52

  7. Time to Death From Any Cause

    Time frame: Baseline up to Week 52

  8. Percentage of Participants With Lung Transplantation

    Time frame: Baseline up to Week 52

  9. Time to Respiratory-Related Death

    Time frame: Baseline up to Week 52

  10. Change From Baseline to Week 52 in Transthoracic Echocardiography (ECHO) Parameter: Peak Tricuspid Regurgitation Velocity

    Time frame: Baseline, Week 52

  11. Change From Baseline to Week 52 in Transthoracic Echocardiography (ECHO) Parameter: Pulmonary Artery Pressure (PAPs)

    Time frame: Baseline, Week 52

  12. Change From Baseline to Week 52 in Transthoracic Echocardiography (ECHO) Parameter: Tricuspid Annular Plane Systolic Excursion (TAPSE)

    Time frame: Baseline, Week 52

  13. Change From Baseline to Week 52 in Transthoracic Echocardiography (ECHO) Parameter: Right Ventricle Basal Diameter

    Time frame: Baseline, Week 52

  14. Change From Baseline to Week 52 in Transthoracic Echocardiography (ECHO) Parameter: Inferior Vena Cava Diameter

    Time frame: Baseline, Week 52

  15. Change From Baseline to Week 52 in Transthoracic Echocardiography (ECHO) Parameter: Left Ventricular Ejection Fraction (LVEF)

    Time frame: Baseline, Week 52

  16. Change From Baseline to Week 52 in Carbon Monoxide Diffusing Capacity/ Pulmonary Diffusing Capacity (DLCO)

    Time frame: Baseline, Week 52

  17. Change From Baseline to Week 52 in Forced Vital Capacity (FVC)

    Time frame: Baseline, Week 52

  18. Percentage of Participants by World Health Organization (WHO) Functional Class at Week 52

    The World Health Organisation (WHO) functional class system defines the severity of an participant's symptoms. Class II - Participants with Pulmonary Hypertension resulting in slight limitation of physical activity. They are comfortable at rest. Ordinary physical activity causes undue breathlessness, fatigue (tiredness), or activities that can cause chest pain, dizziness or even black outs. Class III - Participants with Pulmonary Hypertension resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary activity causes undue breathlessness, fatigue (tiredness), or activities that can cause chest pain, dizziness or even black outs. Class IV - participants with pulmonary hypertension with inability to carry out any physical activity without symptoms. These participants manifest signs of right heart failure, breathlessness and /or fatigue, which may even be present at rest. Discomfort is increased by any physical activity.

    Time frame: Week 52

  19. Change From Baseline in N-terminal Pro-Brain Natriuretic Peptide (NT-proBNP) Level (pg/mL) at Week 52

    Time frame: Baseline, Week 52

  20. St. George's Respiratory Questionnaire (SGRQ) Changes From Baseline at Week 52

    The SGRQ is a 50-item questionnaire developed to measure health status (quality of life) in participants with diseases of airways obstruction. Three component scores are calculated, where the higher the component result the worse the condition: Symptoms concerned with the effect of respiratory symptoms, their frequency and severity (range: 0-16.61) Activity concerned with activities that cause or are limited by breathlessness (range: 0-30.31) Impacts covers a range of aspects concerned with social functioning and psychological disturbances resulting from airway disease (range: 0- 53.08) Total score summaries the impact of disease on overall health status. Scores are expressed as a percentage of overall impairment where 100 represents worst possible health status and 0 indicates best possible health status.

    Time frame: Baseline, Week 52

  21. University of California, San Diego-Shortness of Breath Questionnaire (UCSD-SOBQ) Changes From Baseline at Week 52

    The UCSD-SOBQ is a respiratory questionnaire and it assesses dyspnea associated with activities of daily living (ADL). Participants indicate severity of SOB on a 6-point scale in 21 ADL. Three additional questions ask about fear of harm from overexertion, limitations and fear caused by SOB. A total score ranges from 0 to 120, with higher scores indicating greater impairment.

    Time frame: Baseline, Week 52

  22. Change From Baseline in Distance Walked, 6-minute Walking Distance (6MWD) Test at Week 52

    Time frame: Baseline up to Week 52

  23. Change From Baseline in Oxygen Requirements, 6-minute Walking Distance (6MWD) Test at Week 52

    Time frame: Baseline up to Week 52

  24. Change From Baseline in Other 6-minute Walking Distance (6MWD) Parameters at Week 52

    Time frame: Baseline up to Week 52

  25. Percentage of Participants With Adverse Events

    Time frame: Baseline up to Week 52 + 28 days

  26. Borg Scale Result at the End of the Test at Week 52

    The Borg Scale rates participant's level of perceived exertion during any activity from 0-10, with 0 being no effort at all and 10 being maximal exertion.

    Time frame: Week 52

07

Results

Posted Nov 12, 2020

Participant flow

Participant flow — Overall Study
MilestonePirfenidone+SildenafilPirfenidone+Placebo
Started8889
Completed166
Not completed7283
Withdrew: Adverse event37
Withdrew: Death2836
Withdrew: Lack of efficacy01
Withdrew: Lost to follow-up01
Withdrew: Lung transplantation96
Withdrew: Other13
Withdrew: Progressive disease11
Withdrew: Withdrawal by subject711
Withdrew: Participant ongoing in the study2317

Outcome measures

PrimaryPercentage of Participants With Disease Progression, as Determined by Relevant Decline in 6 Minute Walk Distance (6MWD) of At Least (>=) 15 Percent (%) From Baseline, Respiratory-Related Non-Elective Hospitalization, or Death From Any Cause

Disease Progression defined as relative decline in 6-minute walking distance (6MWD) from baseline (defined as \>25% from baseline or 15-25% from baseline associated with worsening oxygen saturation, worsening Borg score, or increased oxygen requirements), respiratory-related non-elective hospitalizations, or all-cause mortality.

Time frame:
Baseline up to Week 52
Reported as:
Number · Percentage of Participants
Percentage of Participants With Disease Progression, as Determined by Relevant Decline in 6 Minute Walk Distance (6MWD) of At Least (>=) 15 Percent (%) From Baseline, Respiratory-Related Non-Elective Hospitalization, or Death From Any Cause
Percentage of ParticipantsPirfenidone+SildenafilPirfenidone+Placebo
Percentage of Participants With Disease Progression, as Determined by Relevant Decline in 6 Minute Walk Distance (6MWD) of At Least (>=) 15 Percent (%) From Baseline, Respiratory-Related Non-Elective Hospitalization, or Death From Any Cause72.769.7
Statistical analysis
  • Pirfenidone+Sildenafil vs Pirfenidone+Placebo · Chi-squared · p = 0.6527 · Difference of percentage of participants: 3.06 · 95% CI -11.30 to 17.97
SecondaryTime to First Occurrence of Disease Progression

Disease Progression defined as relative decline in 6MWD from baseline (defined as \>25% from baseline or 15-25% from baseline associated with worsening oxygen saturation, worsening Borg score, or increased oxygen requirements), respiratory-related non-elective hospitalizations, or all-cause mortality.

Time frame:
Baseline up to Week 52
Reported as:
Median · Weeks
Time to First Occurrence of Disease Progression
WeeksPirfenidone+SildenafilPirfenidone+Placebo
Time to First Occurrence of Disease Progression26.00 (20.57 to 38.14)25.43 (13.00 to 37.71)
Statistical analysis
  • Pirfenidone+Sildenafil vs Pirfenidone+Placebo · Log Rank · p = 0.7568 · Hazard ratio (hr): 0.95 · 95% CI 0.67 to 1.34Log-rank test based on the time to the first event to compare the two treatment arms.
SecondaryTime to Multiple Occurrence of Disease Progression Events

Disease Progression defined as relative decline in 6MWD from baseline (defined as \>25% from baseline or 15-25% from baseline associated with worsening oxygen saturation, worsening Borg score, or increased oxygen requirements), respiratory-related non-elective hospitalizations, or all-cause mortality. In case participant had more than one event as described in the endpoint definition the second, third etc event was counted as well for the calculation of the endpoint.

Time frame:
Baseline up to Week 52
Reported as:
Median · Weeks
Time to Multiple Occurrence of Disease Progression Events
WeeksPirfenidone+SildenafilPirfenidone+Placebo
Time to Multiple Occurrence of Disease Progression Events20.57 (13.14 to 26.43)13.29 (12.71 to 23.29)
Statistical analysis
  • Pirfenidone+Sildenafil vs Pirfenidone+Placebo · Log Rank · p = 0.3760 · Hazard ratio (hr): 0.89 · 95% CI 0.68 to 1.15Log-rank test based on the time to the first event to compare the two treatment arms.
SecondaryPercentage of Participants With Decline From Baseline in 6-minute Walking Distance (6MWD) of >= 15%
Time frame:
Baseline up to Week 52
Reported as:
Number · Percentage
Percentage of Participants With Decline From Baseline in 6-minute Walking Distance (6MWD) of >= 15%
PercentagePirfenidone+SildenafilPirfenidone+Placebo
Percentage of Participants With Decline From Baseline in 6-minute Walking Distance (6MWD) of >= 15%53.450.6
Statistical analysis
  • Pirfenidone+Sildenafil vs Pirfenidone+Placebo · Chi-squared · p = 0.7046 · Difference (95% ci): 2.85 · 95% CI -12.13 to 17.84
SecondaryTime to First Occurrence of Relevant ≥15% Decline From Baseline in 6-minute Walking Distance (6MWD)
Time frame:
Baseline up to Week 52
Reported as:
Median · Weeks
Time to First Occurrence of Relevant ≥15% Decline From Baseline in 6-minute Walking Distance (6MWD)
WeeksPirfenidone+SildenafilPirfenidone+Placebo
Time to First Occurrence of Relevant ≥15% Decline From Baseline in 6-minute Walking Distance (6MWD)39.00 (27.86 to 52.14)38.71 (25.14 to 52.57)
Statistical analysis
  • Pirfenidone+Sildenafil vs Pirfenidone+Placebo · Log Rank · p = 0.7550 · Difference (95% ci): 0.94 · 95% CI 0.62 to 1.41
SecondaryTime to Respiratory-Related Non-Elective Hospitalization From Baseline to Week 52

N.A. = non-calculable

Time frame:
Baseline up to Week 52
Reported as:
Median · Weeks
Time to Respiratory-Related Non-Elective Hospitalization From Baseline to Week 52
WeeksPirfenidone+SildenafilPirfenidone+Placebo
Time to Respiratory-Related Non-Elective Hospitalization From Baseline to Week 5254.29 (36.29 to NA)NA (42.14 to NA)
Statistical analysis
  • Pirfenidone+Sildenafil vs Pirfenidone+Placebo · Log Rank · p = 0.9174 · Hazard ratio (hr): 1.02 · 95% CI 0.65 to 1.61
SecondaryTime to All-Cause Non-Elective Hospitalization

N.A. = non-calculable

Time frame:
Baseline up to Week 52
Reported as:
Median · Weeks
Time to All-Cause Non-Elective Hospitalization
WeeksPirfenidone+SildenafilPirfenidone+Placebo
Time to All-Cause Non-Elective Hospitalization47.57 (28.00 to NA)49.86 (32.00 to NA)
Statistical analysis
  • Pirfenidone+Sildenafil vs Pirfenidone+Placebo · Log Rank · p = 0.7748 · Hazard ratio (hr): 1.06 · 95% CI 0.70 to 1.62
SecondaryTime to Death From Any Cause
Time frame:
Baseline up to Week 52
Reported as:
Median · Weeks
Time to Death From Any Cause
WeeksPirfenidone+SildenafilPirfenidone+Placebo
Time to Death From Any CauseNA (54.43 to NA)NA (NA to NA)
Statistical analysis
  • Pirfenidone+Sildenafil vs Pirfenidone+Placebo · Log Rank · p = 0.4258 · Hazard ratio (hr): 0.76 · 95% CI 0.38 to 1.50
SecondaryPercentage of Participants With Lung Transplantation
Time frame:
Baseline up to Week 52
Reported as:
Number · Percentage
Percentage of Participants With Lung Transplantation
PercentagePirfenidone+SildenafilPirfenidone+Placebo
Percentage of Participants With Lung Transplantation10.26.7
SecondaryTime to Respiratory-Related Death
Time frame:
Baseline up to Week 52
Reported as:
Median · Weeks
Time to Respiratory-Related Death
WeeksPirfenidone+SildenafilPirfenidone+Placebo
Time to Respiratory-Related DeathNA (54.43 to NA)NA (NA to NA)
Statistical analysis
  • Pirfenidone+Sildenafil vs Pirfenidone+Placebo · Log Rank · p = 0.3161 · Hazard ratio (hr): 0.67 · 95% CI 0.31 to 1.47
SecondaryChange From Baseline to Week 52 in Transthoracic Echocardiography (ECHO) Parameter: Peak Tricuspid Regurgitation Velocity
Time frame:
Baseline, Week 52
Reported as:
Mean · m/s
Change From Baseline to Week 52 in Transthoracic Echocardiography (ECHO) Parameter: Peak Tricuspid Regurgitation Velocity
m/sPirfenidone+SildenafilPirfenidone+Placebo
Change From Baseline to Week 52 in Transthoracic Echocardiography (ECHO) Parameter: Peak Tricuspid Regurgitation Velocity-0.014 ± 0.63260.103 ± 0.6699
SecondaryChange From Baseline to Week 52 in Transthoracic Echocardiography (ECHO) Parameter: Pulmonary Artery Pressure (PAPs)
Time frame:
Baseline, Week 52
Reported as:
Mean · mmHg
Change From Baseline to Week 52 in Transthoracic Echocardiography (ECHO) Parameter: Pulmonary Artery Pressure (PAPs)
mmHgPirfenidone+SildenafilPirfenidone+Placebo
Change From Baseline to Week 52 in Transthoracic Echocardiography (ECHO) Parameter: Pulmonary Artery Pressure (PAPs)2.0 ± 15.653.6 ± 22.38
SecondaryChange From Baseline to Week 52 in Transthoracic Echocardiography (ECHO) Parameter: Tricuspid Annular Plane Systolic Excursion (TAPSE)
Time frame:
Baseline, Week 52
Reported as:
Mean · cm
Change From Baseline to Week 52 in Transthoracic Echocardiography (ECHO) Parameter: Tricuspid Annular Plane Systolic Excursion (TAPSE)
cmPirfenidone+SildenafilPirfenidone+Placebo
Change From Baseline to Week 52 in Transthoracic Echocardiography (ECHO) Parameter: Tricuspid Annular Plane Systolic Excursion (TAPSE)-0.204 ± 0.4170-0.146 ± 0.4453
SecondaryChange From Baseline to Week 52 in Transthoracic Echocardiography (ECHO) Parameter: Right Ventricle Basal Diameter
Time frame:
Baseline, Week 52
Reported as:
Mean · cm
Change From Baseline to Week 52 in Transthoracic Echocardiography (ECHO) Parameter: Right Ventricle Basal Diameter
cmPirfenidone+SildenafilPirfenidone+Placebo
Change From Baseline to Week 52 in Transthoracic Echocardiography (ECHO) Parameter: Right Ventricle Basal Diameter0.462 ± 1.23050.095 ± 1.2875
SecondaryChange From Baseline to Week 52 in Transthoracic Echocardiography (ECHO) Parameter: Inferior Vena Cava Diameter
Time frame:
Baseline, Week 52
Reported as:
Mean · cm
Change From Baseline to Week 52 in Transthoracic Echocardiography (ECHO) Parameter: Inferior Vena Cava Diameter
cmPirfenidone+SildenafilPirfenidone+Placebo
Change From Baseline to Week 52 in Transthoracic Echocardiography (ECHO) Parameter: Inferior Vena Cava Diameter-0.05 ± 0.595-0.09 ± 0.540
SecondaryChange From Baseline to Week 52 in Transthoracic Echocardiography (ECHO) Parameter: Left Ventricular Ejection Fraction (LVEF)
Time frame:
Baseline, Week 52
Reported as:
Mean · Percentage
Change From Baseline to Week 52 in Transthoracic Echocardiography (ECHO) Parameter: Left Ventricular Ejection Fraction (LVEF)
PercentagePirfenidone+SildenafilPirfenidone+Placebo
Change From Baseline to Week 52 in Transthoracic Echocardiography (ECHO) Parameter: Left Ventricular Ejection Fraction (LVEF)1.22 ± 9.166-0.85 ± 5.767
SecondaryChange From Baseline to Week 52 in Carbon Monoxide Diffusing Capacity/ Pulmonary Diffusing Capacity (DLCO)
Time frame:
Baseline, Week 52
Reported as:
Mean · Percentage Predicted
Change From Baseline to Week 52 in Carbon Monoxide Diffusing Capacity/ Pulmonary Diffusing Capacity (DLCO)
Percentage PredictedPirfenidone+SildenafilPirfenidone+Placebo
Change From Baseline to Week 52 in Carbon Monoxide Diffusing Capacity/ Pulmonary Diffusing Capacity (DLCO)-2.918 ± 6.2296-2.440 ± 8.2820
SecondaryChange From Baseline to Week 52 in Forced Vital Capacity (FVC)
Time frame:
Baseline, Week 52
Reported as:
Mean · Percentage Predicted
Change From Baseline to Week 52 in Forced Vital Capacity (FVC)
Percentage PredictedPirfenidone+SildenafilPirfenidone+Placebo
Change From Baseline to Week 52 in Forced Vital Capacity (FVC)-2.761 ± 7.8044-1.616 ± 11.1158
SecondaryPercentage of Participants by World Health Organization (WHO) Functional Class at Week 52

The World Health Organisation (WHO) functional class system defines the severity of an participant's symptoms. Class II - Participants with Pulmonary Hypertension resulting in slight limitation of physical activity. They are comfortable at rest. Ordinary physical activity causes undue breathlessness, fatigue (tiredness), or activities that can cause chest pain, dizziness or even black outs. Class III - Participants with Pulmonary Hypertension resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary activity causes undue breathlessness, fatigue (tiredness), or activities that can cause chest pain, dizziness or even black outs. Class IV - participants with pulmonary hypertension with inability to carry out any physical activity without symptoms. These participants manifest signs of right heart failure, breathlessness and /or fatigue, which may even be present at rest. Discomfort is increased by any physical activity.

Time frame:
Week 52
Reported as:
Number · Percentage
Percentage of Participants by World Health Organization (WHO) Functional Class at Week 52
PercentagePirfenidone+SildenafilPirfenidone+Placebo
Class II19.313.5
Class III33.024.7
Class IV3.41.1
Missing01.1
SecondaryChange From Baseline in N-terminal Pro-Brain Natriuretic Peptide (NT-proBNP) Level (pg/mL) at Week 52
Time frame:
Baseline, Week 52
Reported as:
Mean · pg/mL)
Change From Baseline in N-terminal Pro-Brain Natriuretic Peptide (NT-proBNP) Level (pg/mL) at Week 52
pg/mL)Pirfenidone+SildenafilPirfenidone+Placebo
Change From Baseline in N-terminal Pro-Brain Natriuretic Peptide (NT-proBNP) Level (pg/mL) at Week 52110.1 ± 612.98605.9 ± 1273.19
Statistical analysis
  • Pirfenidone+Sildenafil vs Pirfenidone+Placebo · Linear Mixed Effects Model · p = 0.5646 · Difference in mean change from baseline: -206.59 · 95% CI -920.03 to 506.85
SecondarySt. George's Respiratory Questionnaire (SGRQ) Changes From Baseline at Week 52

The SGRQ is a 50-item questionnaire developed to measure health status (quality of life) in participants with diseases of airways obstruction. Three component scores are calculated, where the higher the component result the worse the condition: Symptoms concerned with the effect of respiratory symptoms, their frequency and severity (range: 0-16.61) Activity concerned with activities that cause or are limited by breathlessness (range: 0-30.31) Impacts covers a range of aspects concerned with social functioning and psychological disturbances resulting from airway disease (range: 0- 53.08) Total score summaries the impact of disease on overall health status. Scores are expressed as a percentage of overall impairment where 100 represents worst possible health status and 0 indicates best possible health status.

Time frame:
Baseline, Week 52
Reported as:
Mean · Units on a scale
St. George's Respiratory Questionnaire (SGRQ) Changes From Baseline at Week 52
Units on a scalePirfenidone+SildenafilPirfenidone+Placebo
Total score6.149 ± 12.340711.437 ± 12.5187
Symptoms component score2.498 ± 19.60748.261 ± 19.5558
Activities component score3.997 ± 15.434110.871 ± 14.5246
Impacts component score8.417 ± 15.004012.118 ± 15.3487
Statistical analysis
  • Pirfenidone+Sildenafil vs Pirfenidone+Placebo · ANCOVA · p = 0.5255 · Median difference (final values): -3.33 · 95% CI -9.98 to 2.36Difference in mean change in total score: -4.22
SecondaryUniversity of California, San Diego-Shortness of Breath Questionnaire (UCSD-SOBQ) Changes From Baseline at Week 52

The UCSD-SOBQ is a respiratory questionnaire and it assesses dyspnea associated with activities of daily living (ADL). Participants indicate severity of SOB on a 6-point scale in 21 ADL. Three additional questions ask about fear of harm from overexertion, limitations and fear caused by SOB. A total score ranges from 0 to 120, with higher scores indicating greater impairment.

Time frame:
Baseline, Week 52
Reported as:
Mean · Points on scale
University of California, San Diego-Shortness of Breath Questionnaire (UCSD-SOBQ) Changes From Baseline at Week 52
Points on scalePirfenidone+SildenafilPirfenidone+Placebo
University of California, San Diego-Shortness of Breath Questionnaire (UCSD-SOBQ) Changes From Baseline at Week 5212.5 ± 20.9318.8 ± 19.68
Statistical analysis
  • Pirfenidone+Sildenafil vs Pirfenidone+Placebo · ANCOVA · p = 0.4263 · Median difference (final values): -6.00 · 95% CI -18.00 to 6.00Difference in mean change in total score: -5.07
SecondaryChange From Baseline in Distance Walked, 6-minute Walking Distance (6MWD) Test at Week 52
Time frame:
Baseline up to Week 52
Reported as:
Mean · meters
Change From Baseline in Distance Walked, 6-minute Walking Distance (6MWD) Test at Week 52
metersPirfenidone+SildenafilPirfenidone+Placebo
Change From Baseline in Distance Walked, 6-minute Walking Distance (6MWD) Test at Week 52-52.9 ± 121.07-40.8 ± 91.26
SecondaryChange From Baseline in Oxygen Requirements, 6-minute Walking Distance (6MWD) Test at Week 52
Time frame:
Baseline up to Week 52
Reported as:
Mean · L
Change From Baseline in Oxygen Requirements, 6-minute Walking Distance (6MWD) Test at Week 52
LPirfenidone+SildenafilPirfenidone+Placebo
Change From Baseline in Oxygen Requirements, 6-minute Walking Distance (6MWD) Test at Week 520.6 ± 1.270.6 ± 1.43
SecondaryChange From Baseline in Other 6-minute Walking Distance (6MWD) Parameters at Week 52
Time frame:
Baseline up to Week 52
Reported as:
Mean · Percentage
Change From Baseline in Other 6-minute Walking Distance (6MWD) Parameters at Week 52
PercentagePirfenidone+SildenafilPirfenidone+Placebo
SpO2 before the test (at rest)-0.5 ± 4.63-0.8 ± 3.77
SpO2 lowest during the test-3.4 ± 8.930.3 ± 5.27
SpO2 after the test0.5 ± 9.97-2.3 ± 6.67
SecondaryPercentage of Participants With Adverse Events
Time frame:
Baseline up to Week 52 + 28 days
Reported as:
Number · Percentage
Percentage of Participants With Adverse Events
PercentagePirfenidone+SildenafilPirfenidone+Placebo
Percentage of Participants With Adverse Events98.993.3
SecondaryBorg Scale Result at the End of the Test at Week 52

The Borg Scale rates participant's level of perceived exertion during any activity from 0-10, with 0 being no effort at all and 10 being maximal exertion.

Time frame:
Week 52
Reported as:
Mean · Points on Scale
Borg Scale Result at the End of the Test at Week 52
Points on ScalePirfenidone+SildenafilPirfenidone+Placebo
Borg Scale Result at the End of the Test at Week 520.9 ± 3.000.7 ± 3.24

Adverse events

Collected over From baseline to primary data cut-off (up to 2 years 7 months). The safety data includes DBP and SFU up to 11-Nov-2019.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pirfenidone+Sildenafil28/88 (31.8%)54/88 (61.4%)53/88 (60.2%)
Pirfenidone+Placebo36/89 (40.4%)55/89 (61.8%)58/89 (65.2%)
Most frequent serious events
Showing 10 of 72
Most frequent serious events
EventPirfenidone+SildenafilPirfenidone+Placebo
Idiopathic pulmonary fibrosisRespiratory, thoracic and mediastinal disorders19/8821/89
DyspnoeaRespiratory, thoracic and mediastinal disorders7/885/89
PneumoniaInfections and infestations7/884/89
Respiratory failureRespiratory, thoracic and mediastinal disorders5/883/89
Lower respiratory tract infectionInfections and infestations4/881/89
Pulmonary fibrosisRespiratory, thoracic and mediastinal disorders4/882/89
Cardiac arrestCardiac disorders1/884/89
Right ventricular failureCardiac disorders3/881/89
DeathGeneral disorders3/881/89
Respiratory tract infectionInfections and infestations2/881/89
Most frequent other events
Showing 10 of 17
Most frequent other events
EventPirfenidone+SildenafilPirfenidone+Placebo
DyspnoeaRespiratory, thoracic and mediastinal disorders22/8817/89
DiarrhoeaGastrointestinal disorders11/882/89
Respiratory tract infectionInfections and infestations9/884/89
BronchitisInfections and infestations6/889/89
Decreased appetiteMetabolism and nutrition disorders6/889/89
CoughRespiratory, thoracic and mediastinal disorders7/889/89
HypotensionVascular disorders6/889/89
FatigueGeneral disorders8/886/89
Upper respiratory tract infectionInfections and infestations8/882/89
Idiopathic pulmonary fibrosisRespiratory, thoracic and mediastinal disorders8/887/89

Baseline characteristics

ITT Population -

Age, Continuous
Age, Continuous(Years)Pirfenidone+SildenafilPirfenidone+PlaceboTotal
Mean68.2 ± 7.768.9 ± 7.168.6 ± 7.4
Sex: Female, Male
Sex: Female, Male(Participants)Pirfenidone+SildenafilPirfenidone+PlaceboTotal
Female192443
Male6965134
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Pirfenidone+SildenafilPirfenidone+PlaceboTotal
Hispanic or Latino235
Not Hispanic or Latino7879157
Unknown or Not Reported8715
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Pirfenidone+SildenafilPirfenidone+PlaceboTotal
American Indian or Alaska Native000
Asian101
Native Hawaiian or Other Pacific Islander101
Black or African American011
White8588173
More than one race000
Unknown or Not Reported101
08

Study locations

56 sites
  • ULB Hôpital Erasme
    Brussels, 1070, Belgium
  • Cliniques Universitaires St-Luc
    Bruxelles, 1200, Belgium
  • UZ Antwerpen
    Edegem, 2650, Belgium
  • UZ Leuven Gasthuisberg
    Leuven, 3000, Belgium
  • CHU Sart-Tilman
    Liège, 4000, Belgium
  • CHU UCL Mont-Godinne
    Mont-godinne, 5530, Belgium
  • Hotel Dieu Hospital
    Kingston, Ontario K7L 2V7, Canada
  • CHUM Hôpital Notre-Dame
    Montreal, Quebec H2L 4M1, Canada
  • Institut universitaire de cardiologie et de pneumologie de Québec (Hôpital Laval)
    Ste. Foy, Quebec G1V 4G5, Canada
  • Thomayerova nemocnice; Pneumologicka klinika 1.LF UK TN
    Praha 4 - Krc, 140 59, Czechia
  • Clinical Research Center (CRC), Faculty of Medicine, Alexandria University
    Alexandria, 21131, Egypt
  • Kasr El-Aini-Chest Unit; Department 3-Chest Unit
    Cairo, 11562, Egypt
  • Ain Shams University Hospital-Chest unit; Chest unit
    Cairo, 11566, Egypt
  • Fachkrankenhaus Coswig GmbH Zentrum f.Pneumologie Beatmungsmedizin Thorax-u.Gefäßchirurgie
    Coswig, 01640, Germany
  • Klinik Donaustauf Zentrum für Pneumologie
    Donaustauf, 93093, Germany
  • Ruhrlandklinik Lungenzentrum der UNI Essen Abt.Pneumologie-Allergologie
    Essen, 45239, Germany
  • Klinikum Fulda gAG; Universitätsmedizin Marburg, Campus Fulda
    Fulda, 36043, Germany
  • Universitätsklinikum Standort Gießen Medizinische Klinik II u. Poliklinik Innere Med./Pneumologie
    Gießen, 35392, Germany
  • Thoraxklinik Heidelberg gGmbH
    Heidelberg, 69126, Germany
  • Fachklinik für Lungenerkrankungen
    Immenhausen, 34376, Germany
  • Klinikum der Universität München; Campus Großhadern; Med. Klinik und Poliklinik V
    München, 81377, Germany
  • Sotiria Hospital for Diseases of the Chest, Academic Department of Pneumonology
    Athens, 115 27, Greece
  • University General Hospital of Athens "Attikon", B' University Pulmonary Clinic
    Chaidari, 124 62, Greece
  • University General Hospital of Heraklio, Pulmonary Clinic
    Heraklio, 711 10, Greece
  • Semmelweis Egyetem X; Pulmonologiai Klinika
    Budapest, 1083, Hungary
  • Orszagos Koranyi TBC es Pulmonologiai Intezet
    Budapest, 1121, Hungary
  • Soroka; Pulmonary Clinic
    Beer Sheba, 8410101, Israel
  • Carmel Medical Center; Pulmonary Institute
    Haifa, 3436212, Israel
  • Shaare Zedek Medical Center; Pulmonary Inst.
    Jerusalem, 9103102, Israel
  • Hadassah Medical Center; Pulmonary Institute
    Jerusalem, 9112001, Israel
  • Meir Medical Center; Pulmonary Dept
    Kfar Saba, 4428164, Israel
  • Beilinson Medical Center; Pulmonary Inst.
    Petach Tikva, 4941492, Israel
  • Kaplan Medical Center
    Rehovot, 7610001, Israel
  • Ospedale Morgagni-Pierantoni; U.O. Pneumologia
    Forlì, Emilia-Romagna 47121, Italy
  • A.O. Universitaria Policlinico Di Modena; DIP. Malattie Dell'apparato Respiratorio
    Modena, Emilia-Romagna 41124, Italy
  • Ospedale San Giuseppe; U.O. di Pneumologia
    Milano, Lombardia 20123, Italy
  • ASST DI MONZA; U O Clinica Pneumologica
    Monza, Lombardia 20900, Italy
  • A.O.U. Ospedali Riuniti Di Foggia-Ospedale D'avanzo; Malattie Dell'apparato Respiratorio IV
    Foggia, Puglia 71100, Italy
  • A.O.U. Policlinico Vittorio Emanuele; Centro per la cura delle Malattie Rare del Polmone
    Catania, Sicilia 95123, Italy
  • A.O. Univ. Senese Policlinico S. Maria alle Scotte; UOC Malattie Resepiratorie e Trapianto Polmonare
    Siena, Toscana 53100, Italy
  • Azienda Ospedaliera di Padova; Dip. Scienze Cardiologiche Toraciche Vascolari-UOC Pneumologia
    Padova, Veneto 35128, Italy
  • Vu Medisch Centrum; Afdeling Longziekten
    Amsterdam, 1081 HV, Netherlands
  • Erasmus MC
    Rotterdam, 3015 GD, Netherlands
  • University of Cape Town Lung Institute; Lung Clinical Research
    Cape Town, 7700, South Africa
  • Milpark Hospital
    Parktown West, 2196, South Africa
  • University of Stellenbosch; Respiratory Research
    Parow, 7505, South Africa
  • Hospital Universitari de Bellvitge ; Servicio de Neumologia
    Hospitalet de Llobregat, Barcelona 08097, Spain
  • Hospital Universitario Marques de Valdecilla; Servicio de neumologia
    Santander, Cantabria 39008, Spain
  • Hospital Universitario Puerta de Hierro Majadahonda; Servicio de Neumología
    Majadahonda, Madrid 28222, Spain
  • Hospital Clinic I provincial; Servicio de Neumologia
    Barcelona, 08036, Spain
  • Hospital Universitario la Fe; Servicio de Neumologia
    Valencia, 46009, Spain
  • Ankara Uni Faculty of Medicine; Chest Diseases
    Ankara, 06100, Turkey
  • Uludag University; Pulmonology and Allergy Department
    Bursa, 16059, Turkey
  • Yedikule Gogus Hastaliklari ve Gogus Cerrahisi EAH;Gogus Hastaliklari
    Istanbul, 34020, Turkey
  • Istanbul Universitesi Capa Tıp Fakültesi; Gogus Hastalıkları Anabilim dalı
    Istanbul, 34093, Turkey
  • Ege Universitesi Tıp Fakültesi; Gögüs Hastalıkları Bilim Dalı
    İzmir, 35040, Turkey
09

References and documents

Publications

  • Behr J, Nathan SD, Wuyts WA, Mogulkoc Bishop N, Bouros DE, Antoniou K, Guiot J, Kramer MR, Kirchgaessler KU, Bengus M, Gilberg F, Perjesi A, Harari S, Wells AU. Efficacy and safety of sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: a double-blind, randomised, placebo-controlled, phase 2b trial. Lancet Respir Med. 2021 Jan;9(1):85-95. doi: 10.1016/S2213-2600(20)30356-8. Epub 2020 Aug 18. Erratum In: Lancet Respir Med. 2021 Apr;9(4):e38. doi: 10.1016/S2213-2600(21)00094-1. PubMed 32822614 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2016 to primary completion in Sep 2019, 32 months.

Results were first posted in Nov 2020, 1 year 1 month after primary completion.

Of 63 industry-sponsored phase 2 interventional studies under Idiopathic Pulmonary Fibrosis, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 45. This study's 32 months is above that.

Counting every sponsor, half of 76 studies reached it within 30 months; a quarter within 21 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 28, 2016
First posted
Nov 1, 2016
StartActual
Dec 31, 2016
Primary completionActual
Sep 26, 2019
CompletionActual
Aug 22, 2020
Results first posted
Nov 12, 2020
Last update
Nov 12, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 12, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02951429
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Nov 1, 2016
Start date
Dec 31, 2016
Primary completion
Sep 26, 2019
Completion
Aug 22, 2020
Results posted
Nov 12, 2020
Last update
Nov 12, 2020

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sildenafil

Start the discussion